Alkem Laboratories Limited Stock price

Equities

ALKEM

INE540L01014

Pharmaceuticals

Market Closed - NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
4,942 INR -1.24% Intraday chart for Alkem Laboratories Limited +3.30% -5.01%
Sales 2024 * 129B 1.55B Sales 2025 * 143B 1.71B Capitalization 591B 7.09B
Net income 2024 * 18.78B 225M Net income 2025 * 21.9B 263M EV / Sales 2024 * 4.4 x
Net cash position 2024 * 22.27B 267M Net cash position 2025 * 27.64B 331M EV / Sales 2025 * 3.95 x
P/E ratio 2024 *
31.8 x
P/E ratio 2025 *
27.1 x
Employees 16,871
Yield 2024 *
0.87%
Yield 2025 *
0.98%
Free-Float 36.2%
More Fundamentals * Assessed data
Dynamic Chart
Alkem Laboratories Forms Subsidiary for Medical Devices Business MT
Alkem Laboratories Gets 10 Observations from US FDA After Baddi, India Unit Inspection MT
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy MT
Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,470 From INR3,960, Keeps at Underperform MT
Transcript : Alkem Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024
Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024 CI
Alkem Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Indian Equities Close Higher on Friday, Lifted by IT Stocks MT
Alkem Laboratories Names Successor to Outgoing CFO MT
Alkem Laboratories Limited Announces CFO Changes CI
Heritage Global, Investors Acquire Pharmaceutical Plant from Alkem Laboratories MT
Federal Machinery & Equipment Co., Heritage Global Partners, Inc., New Mill Capital LLC, Keith Machinery Corp acquired Pharmaceutical Site in Fenton Missouri from Alkem Laboratories Limited. CI
Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023 CI
Alkem Laboratories Limited Submits Clinical Trial Application to Central Drugs Standard Control Organization in India CI
Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy CI
More news
1 day-1.24%
1 week+3.30%
Current month-3.61%
1 month-2.02%
3 months-2.63%
6 months+38.84%
Current year-5.01%
More quotes
1 week
4 650.00
Extreme 4650
5 059.10
1 month
4 650.00
Extreme 4650
5 225.00
Current year
4 650.00
Extreme 4650
5 520.00
1 year
3 186.30
Extreme 3186.3
5 520.00
3 years
2 655.05
Extreme 2655.05
5 520.00
5 years
1 660.00
Extreme 1660
5 520.00
10 years
1 152.50
Extreme 1152.5
5 520.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-09-21
Director of Finance/CFO - Jan. 31
Compliance Officer 54 06-10-31
Members of the board TitleAgeSince
Chief Executive Officer 84 73-08-07
Director/Board Member 41 13-08-08
Director/Board Member 61 87-12-31
More insiders
Date Price Change Volume
24-03-28 4,942 -1.24% 427,458
24-03-27 5,004 +0.04% 89,989
24-03-26 5,002 +4.43% 199,779
24-03-22 4,790 -0.13% 138,264
24-03-21 4,796 +0.25% 275,225

Delayed Quote NSE India S.E., March 28, 2024 at 08:01 am EDT

More quotes
Alkem Laboratories Limited is an India-based company, which is engaged in the pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Company’s product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The Company operates through a segment, Pharmaceuticals. It has approximately 21 manufacturing facilities at multiple locations in India and the United States. The Company has approximately 800 brands and operates in 40 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
4,942 INR
Average target price
5,170 INR
Spread / Average Target
+4.62%
Consensus
  1. Stock
  2. Equities
  3. Stock Alkem Laboratories Limited - NSE India S.E.